MARKET

MREO

MREO

Mereo Biopharma
NASDAQ
2.620
+0.120
+4.80%
After Hours: 2.680 +0.06 +2.29% 19:11 03/14 EDT
OPEN
2.520
PREV CLOSE
2.500
HIGH
2.660
LOW
2.510
VOLUME
682.09K
TURNOVER
--
52 WEEK HIGH
5.02
52 WEEK LOW
2.250
MARKET CAP
406.48M
P/E (TTM)
-10.5901
1D
5D
1M
3M
1Y
5Y
1D
Hidden Gems: 5 Stocks Under $10 With Massive Growth Potential
NASDAQ · 4d ago
Weekly Report: what happened at MREO last week (0303-0307)?
Weekly Report · 5d ago
Mereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Healthcare Conference
Barchart · 03/05 06:30
Weekly Report: what happened at MREO last week (0224-0228)?
Weekly Report · 03/03 10:25
Weekly Report: what happened at MREO last week (0217-0221)?
Weekly Report · 02/24 10:25
Weekly Report: what happened at MREO last week (0210-0214)?
Weekly Report · 02/17 10:23
Mereo BioPharma: Good Science, Fairly Valued
Seeking Alpha · 02/11 20:22
Weekly Report: what happened at MREO last week (0203-0207)?
Weekly Report · 02/10 10:20
More
About MREO
Mereo BioPharma Group plc is a biopharmaceutical company focused on the development of therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). In addition to the rare disease programs, it has two oncology product candidates in clinical development. Etigilimab is an IgG1 monoclonal antibody which binds to the human T-cell immunoreceptor with Ig and ITIM domains (TIGIT) receptor on immune cells to improve the activation and effectiveness of T-cell and NK cell antitumor activity. Navicixizumab is a bispecific antibody that inhibits delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF). Navicixizumab is developed for the treatment of late line ovarian cancer.

Webull offers Mereo BioPharma Group plc - ADR stock information, including NASDAQ: MREO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MREO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MREO stock methods without spending real money on the virtual paper trading platform.